Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Hemodialysis (inpatient and outpatient settings)(Approved)
Status note Taurolidine and heparin; launched commercially in the U.S. in 2024. BARDA government contract in place (product not specified in excerpts).
REZZAYO
Approved · Active
Aliases rezafungin for injection
Partnerships Melinta Therapeutics: acquired by CorMedix Aug 29, 2025 ($453.7M); U.S. commercialization rights; Napp/Mundipharma: acquired global REZZAYO rights from Cidara (Apr 2024); $30-40M regulatory milestone on marketing approval for the prophylaxis indication
Indications
Candidemia and invasive candidiasis (adults)(Approved)
Prophylaxis of invasive fungal diseases in allogeneic BMT/HSCT (adults)(Phase 3)
Catalysts
— 2027
Status note Approved for candidemia and invasive candidiasis in adults. Positive Phase III topline from ReSPECT (prophylaxis of invasive fungal diseases in allogeneic BMT/HSCT) announced Apr 27, 2026; commercialization in the second indication targeted from 2027 if FDA-approved.
MINOCIN IV
Approved · Active
Indications
Acinetobacter infections(Approved)
Status note Acquired via Melinta; one of few agents approved for Acinetobacter species.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Central Line Associated Blood Stream Infections (CLABSI)
—
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.